To include your compound in the COVID-19 Resource Center, submit it here.

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

Kriya plans to extend gene therapies to prevalent, chronic diseases

A team of gene therapy veterans from the likes of Sangamo, Spark and AveXis have debuted Kriya with an untranched $80.5 million series A round to bring gene therapies to patients with prevalent and severe chronic diseases, starting with diabetes and obesity. To facilitate that goal, it’s focusing simultaneously on R&D and building infrastructure, including in-house manufacturing.

Founded in 2019, Kriya Therapeutics Inc. is starting with two preclinical adeno-associated virus (AAV) gene therapies licensed from Autonomous University of Barcelona

Read the full 789 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE